Sagent To Acquire Other Half Of Kanghong Sagent JV For $25 Million
This article was originally published in PharmAsia News
U.S.-based Sagent Pharmaceuticals said it plans to acquire all of China's Kanghong Sagent Pharmaceutical in a buyout estimated at $25 million and make the company a subsidiary.
You may also be interested in...
The first vaccine for the new coronavirus has entered the clinic, with US firm Moderna leading the race.
Korean vaccine specialist SK Bioscience moves to develop versatile platform technology to deal with outbreaks of infectious diseases such as the new coronavirus, as the number of infections in the country surges.
Israel-based Binah.ai hopes to earn regulatory approval for a video-based monitoring app that can detect vital signs in minutes. See what Binah.ai's co-founder and CEO, David Maman, said about the technology here.